Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivanib alaninate - ZAI Lab

Next Previous
X
Search
Drug Profile

Brivanib alaninate - ZAI Lab

Alternative Names: BMS-540215; BMS-582664; Brivanib; ZL-2301

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Gynecologic Oncology Group; Hunan Cancer Hospital; National Cancer Institute (USA); ZAI Lab
  • Class Antineoplastics; Esters; Indoles; Pyrroles; Small molecules; Triazines
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Liver cancer
  • Phase I/II Cholangiocarcinoma
  • No development reported Ovarian cancer; Solid tumours
  • Discontinued Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 08 Jun 2022 ZAI Lab terminates a phase I/II trial in Liver cancer nad Cholangiocarcinoma (In adults, In the elderly, Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV) due to the rapid shifting of liver cancer disease landscape and the company's adjustment of development strategy (NCT04212221)
  • 28 Feb 2022 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Second-line therapy or greater) in China (PO)
  • 04 Jun 2021 Adverse events data from phase II trial in Cervical cancerwas presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top